Condition: Angelman Syndrome · Sponsor: Ionis Pharmaceuticals, Inc.
The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals · (844) 200-6263 · IonisAngelmanStudy@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Colorado Children's Hospital Research Institute | Aurora, Colorado, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| University of North Carolina at Chapel Hill School of Medicine | Carrboro, North Carolina, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Active Not Recruiting |
| Sydney Children's Hospital, Kids Cancer Centre | Randwick, Australia | Active Not Recruiting |
| Necker-Enfants Malades Hospital | Paris, France | Recruiting |
| Sheba Medical Center | Ramat Gan, Israel | Recruiting |
| Azienda Ospedaliera Universitaria Pisana | Pisa, Italy | Recruiting |
| STRONG Group University of Oxford | Oxford, Oxfordshire, United Kingdom | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05127226